Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Net Cash Flow (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Net Cash Flow for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 107.31% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$13.4 million through Dec 2025, down 14.82% year-over-year, with the annual reading at -$13.4 million for FY2025, 0.84% down from the prior year.
  • Net Cash Flow for Q4 2025 was $1.1 million at Artiva Biotherapeutics, up from -$3.0 million in the prior quarter.
  • The five-year high for Net Cash Flow was $21.6 million in Q3 2024, with the low at -$15.6 million in Q4 2024.
  • Average Net Cash Flow over 3 years is -$2.5 million, with a median of -$4.1 million recorded in 2024.
  • Peak annual rise in Net Cash Flow hit 107.31% in 2025, while the deepest fall reached 113.79% in 2025.
  • Over 3 years, Net Cash Flow stood at -$12.4 million in 2023, then fell by 26.37% to -$15.6 million in 2024, then soared by 107.31% to $1.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $1.1 million, -$3.0 million, and -$2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.